Abcellera Biologics Inc (ABCL)vsRevolution Medicines Inc (RVMD)
ABCL
Abcellera Biologics Inc
$5.74
-11.77%
HEALTHCARE · Cap: $1.60B
RVMD
Revolution Medicines Inc
$169.77
+0.15%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Abcellera Biologics Inc generates 10575% more annual revenue ($79.21M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -181.7%. ABCL earns a higher WallStSmart Score of 41/100 (D).
ABCL
Hold41
out of 100
Grade: D
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.7%
Fair Value
$8.86
Current Price
$5.74
$3.12 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 96.3% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Earnings expanding 45.9% YoY
Conservative balance sheet, low leverage
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -15.3% — below average capital efficiency
Negative free cash flow — burning cash
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABCL
The strongest argument for ABCL centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 96.3% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : ABCL
The primary concerns for ABCL are Altman Z-Score, Market Cap, Return on Equity.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
ABCL profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
ABCL is growing revenue faster at 96.3% — sustainability is the question.
ABCL generates stronger free cash flow (-37M), providing more financial flexibility.
Bottom Line
ABCL scores higher overall (41/100 vs 24/100) and 96.3% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abcellera Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?